Literature DB >> 8061832

Pharmacokinetics of honokiol after intravenous administration in rats assessed using high-performance liquid chromatography.

T H Tsai1, C J Chou, F C Cheng, C F Chen.   

Abstract

A simple and sensitive high-performance liquid chromatographic method for the identification and determination of honokiol in rat plasma has been developed. Up to 0.1 ml of plasma containing honokiol was deproteinized with acetonitrile, which contained an internal standard (paeonol). The supernatant was injected onto a reversed-phase C18 column using acetonitrile-water (70:30, v/v, adjusted to pH 2.5-2.8 with orthophosphoric acid) as the mobile phase and ultraviolet detection at 290 nm, followed by UV spectrum identification (between 220 and 380 nm) with a photodiode-array detector. The method was applied to pharmacokinetic studies of honokiol in rat following 5 or 10 mg/kg intravenous administration. A biphasic process consisting of a rapid distribution phase followed by a slower elimination phase was observed from the plasma concentration-time curves. Compartmental analysis yielded a two-compartment model.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8061832     DOI: 10.1016/0378-4347(94)00031-x

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  16 in total

1.  Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).

Authors:  Chandraiah Godugu; Ravi Doddapaneni; Mandip Singh
Journal:  Colloids Surf B Biointerfaces       Date:  2017-01-23       Impact factor: 5.268

2.  Honokiol activates reactive oxygen species-mediated cytoprotective autophagy in human prostate cancer cells.

Authors:  Eun-Ryeong Hahm; Kozue Sakao; Shivendra V Singh
Journal:  Prostate       Date:  2014-07-07       Impact factor: 4.104

3.  Honokiol inhibits androgen receptor activity in prostate cancer cells.

Authors:  Eun-Ryeong Hahm; A Isabella Karlsson; Michael Y Bonner; Jack L Arbiser; Shivendra V Singh
Journal:  Prostate       Date:  2013-12-11       Impact factor: 4.104

4.  Honokiol Decreases Lung Cancer Metastasis through Inhibition of the STAT3 Signaling Pathway.

Authors:  Jing Pan; Yongik Lee; Qi Zhang; Donghai Xiong; Tina C Wan; Yian Wang; Ming You
Journal:  Cancer Prev Res (Phila)       Date:  2016-11-14

5.  Honokiol: a potent chemotherapy candidate for human colorectal carcinoma.

Authors:  Fei Chen; Tao Wang; Yi-Feng Wu; Ying Gu; Xiao-Li Xu; Shu Zheng; Xun Hu
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

6.  The Pharmacokinetics and Tissue Distribution of Honokiol and its Metabolites in Rats.

Authors:  Wang Jun-Jun; Miao Xiao-Lei; Chen Jing-Ya; Chen Yong
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

7.  Honokiol confers immunogenicity by dictating calreticulin exposure, activating ER stress and inhibiting epithelial-to-mesenchymal transition.

Authors:  Shing-Hwa Liu; Wen-Jane Lee; De-Wei Lai; Sheng-Mao Wu; Chia-Yu Liu; Hsing-Ru Tien; Chien-Shan Chiu; Yen-Chun Peng; Yee-Jee Jan; Te-Hsin Chao; Hung-Chuan Pan; Meei-Ling Sheu
Journal:  Mol Oncol       Date:  2015-01-06       Impact factor: 6.603

8.  c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells.

Authors:  Eun-Ryeong Hahm; Krishna Beer Singh; Shivendra V Singh
Journal:  Cell Cycle       Date:  2016-06-24       Impact factor: 4.534

9.  Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells.

Authors:  Avalon Garcia; Yang Zheng; Chen Zhao; Alfredo Toschi; Judy Fan; Natalie Shraibman; H Alex Brown; Dafna Bar-Sagi; David A Foster; Jack L Arbiser
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

Review 10.  Honokiol: a novel natural agent for cancer prevention and therapy.

Authors:  S Arora; S Singh; G A Piazza; C M Contreras; J Panyam; A P Singh
Journal:  Curr Mol Med       Date:  2012-12       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.